Amol Akhade: What’s coming up for Lung Cancer In ESMO 24
Amol Akhade shared a post on LinkedIn:
“What’s coming up for Lung Cancer In ESMO 24 ?
Phase 3 data
1- adjuvant durvalumab alone in completely resected NSCLC
2- second interim OS from Mariposa-2 trial
3 – low dose vs standard dose pembrolizumab for first line NSCLC
NVALT30 trial- first interim analysis
4 – Adagrasib vs Docetaxel in Krystal -12 – advanced NSCLC with KRAS G12C mutation
5- CtDNA clearance data from AEGEAN trial
6- clinical update from Checkmate 77T
7- analysis of CNS and distant progression From Laura trial
Exciting phase 2 data with newer molecules
1 – BMS-986012 ( Anti Fucosyl GM1 antibody ) plus Nivo plus Etoposide – carboplatin in first line Advanced SCLC
2 – Galaxies Lung -201
Belrestotug plus Dostarlimab in First line NSCLC with PDL1 More than 50 %
3 – Nivo plus Relatlimab plus chemo vs Nivo plus chemo for first line NSCLC
Relativity-104 study
4- Zipalertinib – in egfr exon 20 insertions post Amivantamab in Advanced NSCLC.
Which phase 2 data will make it big ?”
Source: Amol Akhade/LinkedIn
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
